Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Aptose Reports Early Safety And Response Results In Phase 1/2 TUSCANY Trial Of Tuspetinib In Combination With Standard Of Care Dosing Of Venetoclax And Azacitidine; Says TUS+VEN+AZA Triplet Achieved Cycle 1 Complete Remission In TP53-Mutated/CK AML

Author: Benzinga Newsdesk | February 12, 2025 07:07am

Posted In: APTO